SEC Filing Analysis: EXACT SCIENCES CORP (EXAS)

Executive Summary

• Trading Significance: Low
• Key Takeaway: An officer at Exact Sciences has filed a notice of proposed sale for 1,500 shares, valued at approximately $105,120. The transaction is pre-planned under a Rule 10b5-1 plan.
• Market Impact: Negligible. The size of the transaction is immaterial relative to the company's market capitalization and the public float.

Company Information

Field	Value
Company	EXACT SCIENCES CORP
Ticker Symbol	EXAS (from analysis, not in filing)
CIK	0001124140
Industry	Medical Laboratories

Insider Information

Field	Value
Name	Herriott James
CIK	0001957680
Title/Position	Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-11-04 (Approximate Sale Date)
Transaction Code	Not Applicable
Security Type	Common Stock
Shares Involved	1,500
Price Per Share	~$70.08 (calculated)
Total Value	$105,120
Shares Owned After	Not Disclosed
Ownership Type	Not Disclosed

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$105,120
% of Market Cap	0.0009%
Shares Transacted	1,500
% of Shares Outstanding	0.0008%
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a market capitalization of $12.25 billion, this $105,120 transaction is financially insignificant and represents a routine portfolio management activity for the insider.
• Transaction Significance: The sale constitutes a negligible percentage of both market capitalization and shares outstanding, falling far below any thresholds for moderate or high significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is extremely small and was arranged under a 10b5-1 trading plan, indicating it is not based on new, non-public information. It is highly unlikely to influence the stock price.

Volume & Sentiment

• Expected Volume Impact: None. The transaction size is too small to have a noticeable effect on daily trading volume.
• Sentiment Indicator: Neutral. This type of routine, pre-planned sale by an officer does not typically affect market sentiment.

Additional Context

Special Circumstances

• The filing indicates the proposed sale is pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2025. This allows insiders to pre-schedule trades to avoid accusations of trading on inside information.